GSC
GALT icon

Ground Swell Capital’s Galectin Therapeutics GALT Stock Holding History

Ground Swell Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2K Buy
333
+233
+233% +$1.81K ﹤0.01% 1887
2014
Q2 		$1K Buy
+100
New +$1.25K ﹤0.01% 1720

Other funds holding GALT

CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Ground Swell Capital's GALT Position: Q3 2014 in Review

Ground Swell Capital increased its Galectin Therapeutics (GALT) stake by 233% in Q3 2014, buying an estimated $1.81K and bringing the position to 333 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1887.

Ground Swell Capital first reported a position in GALT in Q2 2014 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2014.

  • Ground Swell Capital held 333 shares of Galectin Therapeutics worth $2K as of Q3 2014.
  • Ground Swell Capital bought 233 Galectin Therapeutics shares in Q3 2014, an estimated $1.81K.
  • Galectin Therapeutics made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1887 holding.
  • Ground Swell Capital first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.